Specific Genomic Alterations in High-Grade Pulmonary Neuroendocrine Tumours with Carcinoid Morphology
Jérôme Cros, Nathalie Théou–Anton, V. Gounant, Rémy Nicolle, Cécile Réyès, Sarah Humez, S. Hescot, Vincent de Montpréville, Serge Guyétant, Jean‐Yves Scoazec, Alice Guyard, Louis de Mestier, Solenn Brosseau, Pierre Mordant, Yves Castier, David Gentien, Philippe Ruszniewski, Gérard Zalcman, Anne Couvelard, Aurélie Cazes
Abstract
<b><i>Introduction:</i></b> High-grade lung neuroendocrine tumours with carcinoid morphology have been recently reported; they may represent the thoracic counterparts of grade 3 digestive neuroendocrine tumours. We aimed to study their genetic landscape including analysis of tumoral heterogeneity. <b><i>Methods:</i></b> Eleven patients with high-grade (&#x3e;20% Ki-67 and/or &#x3e;10 mitoses) lung neuroendocrine tumours with a carcinoid morphology were included. We analysed copy number variations, somatic mutations, and protein expression in 16 tumour samples (2 samples were available for 5 patients allowing us to study spatial and temporal heterogeneity). <b><i>Results:</i></b> Genomic patterns were heterogeneous ranging from “quiet” to tetraploid, heavily rearranged genomes. Oncogene mutations were rare and most genetic alterations targeted tumour suppressor genes. Chromosomes 11 (7/11), 3 (6/11), 13 (4/11), and 6–17 (3/11) were the most frequently lost. Altered tumour suppressor genes were common to both carcinoids and neuroendocrine carcinomas, involving different pathways including chromatin remodelling (<i>KMT2A</i>, <i>ARID1A</i>, <i>SETD2</i>, <i>SMARCA2</i>, <i>BAP1</i>, <i>PBRM1</i>, <i>KAT6A</i>), DNA repair (<i>MEN1</i>, <i>POLQ</i>, <i>ATR</i>, <i>MLH1</i>, <i>ATM</i>), cell cycle (<i>RB1</i>, <i>TP53</i>, <i>CDKN2A</i>), cell adhesion (<i>LATS2</i>, <i>CTNNB1</i>, <i>GSK3B</i>) and metabolism (<i>VHL</i>). Comparative spatial/temporal analyses confirmed that these tumours emerged from clones of lower aggressivity but revealed that they were genetically heterogeneous accumulating “neuroendocrine carcinoma-like” genetic alterations through progression such as <i>TP53/RB1</i> alterations. <b><i>Conclusion:</i></b> These data confirm the importance of chromatin remodelling genes in pulmonary carcinoids and highlight the potential role of <i>TP53</i> and <i>RB1</i> to drive the transformation in more aggressive high-grade tumours.